Robert W. Baird Upgrades Sensei Biotherapeutics (NASDAQ:FTH) to “Strong-Buy”

Sensei Biotherapeutics (NASDAQ:FTH) was upgraded by equities researchers at Robert W. Baird to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other research firms also recently issued reports on FTH. HC Wainwright began coverage on shares of Sensei Biotherapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $60.00 price objective on the stock. Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. Finally, BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Sensei Biotherapeutics has a consensus rating of “Buy” and an average target price of $58.50.

Sensei Biotherapeutics Stock Down 7.3%

NASDAQ:FTH opened at $22.87 on Thursday. The firm has a market cap of $30.69 million, a P/E ratio of -0.16 and a beta of -0.25. Sensei Biotherapeutics has a one year low of $6.32 and a one year high of $36.76.

Insiders Place Their Bets

In other Sensei Biotherapeutics news, CFO Brian C. Stephenson purchased 9,391 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were purchased at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the purchase, the chief financial officer directly owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This represents a 53.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the stock in a transaction on Monday, June 22nd. The stock was acquired at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the acquisition, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 35,860 shares of company stock valued at $862,703 over the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.